EIP
PDSB icon

Ellis Investment Partners’s PDS Biotechnology PDSB Stock Holding History

Ellis Investment Partners’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,850
Closed -$20K – 578
2022
Q3 		$20K Hold
6,850
– – 0.01% 488
2022
Q2 		$25K Hold
6,850
– – 0.01% 478
2022
Q1 		$42K Buy
6,850
+600
+10% +$3.73K 0.01% 437
2021
Q4 		$50K Hold
6,250
– – 0.01% 424
2021
Q3 		$93K Hold
6,250
– – 0.02% 320
2021
Q2 		$78K Sell
6,250
-1,500
-19% -$11.7K 0.02% 340
2021
Q1 		$35K Sell
7,750
-10,100
-57% -$40.6K 0.01% 435
2020
Q4 		$38K Buy
17,850
+15,600
+693% +$34.2K 0.01% 413
2020
Q3 		$5K Hold
2,250
– – ﹤0.01% 626
2020
Q2 		$3K Hold
2,250
– – ﹤0.01% 653
2020
Q1 		$1K Hold
2,250
– – ﹤0.01% 688
2019
Q4 		$5K Sell
2,250
-1,000
-31% -$2.85K ﹤0.01% 594
2019
Q3 		$10K Hold
3,250
– – ﹤0.01% 536
2019
Q2 		$19K Buy
+3,250
New +$21.3K 0.01% 450

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ellis Investment Partners's PDSB Position: Q4 2022 in Review

Ellis Investment Partners sold out of PDS Biotechnology (PDSB) in Q4 2022, closing a stake of 6,850 shares — an estimated $20K sold.

Ellis Investment Partners first reported a position in PDSB in Q2 2019 and held it in 14 quarters. The position peaked at $93K in Q3 2021. 64 funds tracked by Wall St. Rank hold PDSB as of Q4 2022.

  • Ellis Investment Partners reported no remaining PDS Biotechnology position as of Q4 2022 after selling out during the quarter.
  • Ellis Investment Partners sold 6,850 PDS Biotechnology shares in Q4 2022, an estimated $20K.
  • Ellis Investment Partners first reported a position in PDS Biotechnology in Q2 2019 and held it in 14 quarters.
  • Ellis Investment Partners's PDS Biotechnology position peaked at $93K in Q3 2021.
  • 64 funds tracked by Wall St. Rank held PDS Biotechnology as of Q4 2022.

Based on Ellis Investment Partners's 13F filing for Q4 2022, filed 31 Jan 2023.